Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

779 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus.
Boehncke WH, Brasie RA, Barker J, Chimenti S, Daudén E, de Rie M, Dubertret L, Giannetti A, Katsambas A, Kragballe K, Naeyaert JM, Ortonne JP, Peyrí J, Prinz JC, Saurat JH, Strohal R, van de Kerkhof P, Sterry W; European Dermatology Expert Group. Boehncke WH, et al. Among authors: de rie m, van de kerkhof p. J Eur Acad Dermatol Venereol. 2006 Sep;20(8):988-98. doi: 10.1111/j.1468-3083.2006.01707.x. J Eur Acad Dermatol Venereol. 2006. PMID: 16922950
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, Cameron GS, Erickson J, Zhang L, Secrest RJ, Ball S, Braun DK, Osuntokun OO, Heffernan MP, Nickoloff BJ, Papp K; UNCOVER-2 and UNCOVER-3 investigators. Griffiths CE, et al. Among authors: van de kerkhof p. Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10. Lancet. 2015. PMID: 26072109 Clinical Trial.
European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.
Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N. Nast A, et al. Among authors: de jong em, van de kerkhof p. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2277-94. doi: 10.1111/jdv.13354. Epub 2015 Oct 19. J Eur Acad Dermatol Venereol. 2015. PMID: 26481193 No abstract available.
Efficacy and safety of LAS41008 (dimethyl fumarate) in adults with moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, Fumaderm® - and placebo-controlled trial (BRIDGE).
Mrowietz U, Szepietowski JC, Loewe R, van de Kerkhof P, Lamarca R, Ocker WG, Tebbs VM, Pau-Charles I. Mrowietz U, et al. Among authors: van de kerkhof p. Br J Dermatol. 2017 Mar;176(3):615-623. doi: 10.1111/bjd.14947. Epub 2016 Nov 15. Br J Dermatol. 2017. PMID: 27515097 Clinical Trial.
Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
van de Kerkhof P, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P. van de Kerkhof P, et al. J Eur Acad Dermatol Venereol. 2017 Mar;31(3):477-482. doi: 10.1111/jdv.14033. Epub 2016 Dec 2. J Eur Acad Dermatol Venereol. 2017. PMID: 27910156 Clinical Trial.
779 results